The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 18, 2023

Filed:

May. 20, 2022
Applicant:

Biogaia Ab, Stockholm, SE;

Inventors:

Clara Lucia Garcia-Rodenas, Forel, CH;

Bernard Berger, Maracon, CH;

Catherine Ngom-Bru, Montpreveyres, CH;

Melissa Lepage, Savigny, CH;

Tara Neville, Geneva, CH;

Assignee:

BIOGAIA AB, Stockholm, SE;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/747 (2015.01); A23L 33/00 (2016.01); A23L 33/135 (2016.01); A61K 35/745 (2015.01); A61K 31/702 (2006.01); A61K 31/733 (2006.01); A61K 45/06 (2006.01); A61K 9/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/747 (2013.01); A23L 33/135 (2016.08); A23L 33/40 (2016.08); A61K 9/0053 (2013.01); A61K 31/702 (2013.01); A61K 31/733 (2013.01); A61K 35/745 (2013.01); A61K 45/06 (2013.01); A23V 2002/00 (2013.01); A23Y 2220/71 (2013.01);
Abstract

The invention concernsfor use in the prevention or treatment of microbiota dysbiosis, in particular, decreased levels of Actinobacteria and increased levels of Proteobacteria, in young mammals and in the prevention or treatment of disorders associated therewith. The microbiota dysbiosis may have been cause by numerous factors including being born by caesarean section, exposure to antibiotics in utero or after birth, or, parenteral feeding, hospitalizing, psychological stress or by gastrointestinal dysfunctions. The disorders that may be treated or prevented by preventing or treating microbiota dysbiosis include propensity to infection, allergy, type I diabetes mellitus, insulin resistance, type 2 diabetes, celiac disease, peripheral and central adiposity, obesity, necrotizing enterocolitis, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, and functional gastrointestinal disorders such as IBS, functional diarrhea, functional constipation, recurrent abdominal pain, and dyspepsia.


Find Patent Forward Citations

Loading…